3464 total record number
0 records this year

To narrow your search, use one or more of the following search menus below.

To search by keyword, you may search by type of cell/animal/assay/protein/research or publication.

Page 1 out of 693

A virus hosted in malaria-infected blood protects against T cell-mediated inflammatory diseases by impairing DC function in a type I IFN-dependent manner

Hassan, A;Wlodarczyk, MF;Benamar, M;Bassot, E;
Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer
- µg of killed Mycobacterium tuberculosis (Strain H37a, Difco). Mice were injected intravenously with 200 ng of pertussis toxin (List Biological Laboratories, Campbell, CA, USA) at days 0 and 2 post- immunization. Clinical scores

Bordetella pertussis antigens encapsulated into N-trimethyl chitosan nanoparticulate systems as a novel intranasal pertussis vaccine

Najminejad, H;Kalantar, SM;Mokarram, AR;Dabaghian, M;Abdollahpour-Alitappeh, M;Ebrahimi, SM;Tebianian, M;Fasihi Ramandi, M;Sheikhha, MH;
Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer

Antibody measurements:

For PT-specific IgG ELISA, plates were coated with 0.5 µg/mL purified PT (List Biologicals Campbell, California) in PBS and the assay performed as previously described [133]. ...

Author did not specify which List Labs Pertussis Toxin was utilized.  List Labs provides Product #180 - Pertussis Toxin from B. pertussis, Lyophilized in Buffer and Product #181 - Pertussis Toxin from B. pertussis, Lyophilized (Salt-Free).

PubMed ID: 31240957

Promotion of microglial phagocytosis by tuftsin stimulates remyelination in experimental autoimmune encephalomyelitis

Bao, Z;Hao, J;Li, Y;Feng, F;
Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer
- Technology. Induction of EAE in mice. EAE mice were induced with MOG35-55 (200 µg), and the mice were intraperitoneally injected with pertussis toxin (500 ng, List Biological Laboratories, Inc.) at 0 and 48 h following immunization
PubMed ID: 31702807

QKI-5 is downregulated in CNS inflammatory demyelinating diseases

Lavon, I;leykin, I;Charbit, H;Binyamin, O;Brill, L;Ovadia, H;Vaknin-Dembinsky, A;
Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer
One hundred nanograms of pertussis toxin (List Biological Labs, Campbell, CA, USA) in 0.1 mL saline was also injected intraperitoneally on day 0, and 48 hours later.

Utilization of lipopolysaccharide challenge in cynomolgus macaques to assess IL-10 receptor antagonism

Kamperschroer, C;Goldstein, R;Schneider, PA;Kuang, B;Eisenbraun, MD;
Product: ULTRA PURE LPS from Escherichia coli O111:B4


Ultrapure-grade LPS prepared from Escherichia coli 0111:B4 (List Biologicals, Campbell, CA) was reconstituted in sterile saline at 10 µg/ml and stored in aliquots at −20 °C until use in experiments. The specific bioactivity for the individual lot (4216A2) used for this work was not available, but the predicted activity provided by the vendor based on a similar lot was ≈6.75 × 106 EU/mg (communication from List Biologicals).

In vitro LPS challenge:

Whole blood was collected from animals into sodium heparin tubes (Beckton Dickinson, Caanan, CT) to prevent coagulation. Aliquots (200 µl) of each blood sample were dispensed into 96-well polypropylene plates and placed at 37 °C and 5% CO2 for 30 min. LPS diluted in sterile saline or saline only (control) was added to sample wells (10 µl volume) to achieve final LPS concentrations ranging from 0 to 10 μg/ml. The plates were incubated for an additional 5 h at 37 °C and then centrifuged at 4 °C for 10 min at 600g to pellet the cells. Plasma collected from each well was stored at −80 °C until analyzed. The concentration of TNF in each plasma sample was measured by ELISA using the Monkey TNF ELISA kit (U-CyTech, Utrecht, the Netherlands) according to manufacturer instructions. All samples were measured in duplicate.

In vivo LPS challenge and antibody-based modulation:

Animals (n = 3/group) were injected IV with 1.0 µg LPS/kg in a volume of 0.1 ml/kg. The LPS was first administered on three different days – each separated by a 3-week rest period – to establish baseline LPS responses. Prior to the third LPS challenge, blood samples were collected to perform the in vitro LPS challenge (described above) in order to compare in vitro cytokine responses to those induced in vivo. Following another 3-week rest period, animals were injected IV with 0.1, 1, or 10 mg/kg of anti-IL-10R1 mAb or with 10 mg/kg of the isotype control mAb 2 h before a fourth LPS challenge was administered IV. An additional set of control animals was given 10 mg/kg anti-IL-10R1 mAb IV and left unchallenged (no LPS). After another 3-week rest period, a fifth and final LPS challenge was performed on all groups.

Blood samples were collected into serum separator tubes (Greiner Bio-One, Monroe, NC) just prior to and 1, 2, 4, 6, and 24 h after each LPS challenge to measure concentrations of cytokines (all timepoints) and C-reactive protein (CRP) (pre-challenge and 24 h post-challenge only). Blood samples were also collected just prior to and 0.25, 2, 7, 24, 30, 48, 72, 144, 240, 384, and 552 h immediately after antibody administration to measure serum anti-IL10R mAb levels. Sera prepared from the blood samples by centrifugation were stored at −80 °C (for cytokine and CRP assays) or at −20 °C (for antibody assay) until thawed and analyzed.

PubMed ID: 31464151